Clinical Trial Update: A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating the efficacy of QGE031 compared with omalizumab in patients with allergic asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Omalizumab (Omalizumab)
• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Asthma | Phase 1, Phase 2 | Status: COMPLETED